Advertisement

Topics

Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

11:39 EDT 8 Aug 2017 | Biotech-Finances

Monday, July 31st 2017 at 3:45pm UTC STRASBOURG, France–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated in a Phase 1/2 clinical trial evaluating the combination of Pexa-Vec with Opdivo® (nivolumab) as a first-line treatment of advanced hepatocellular carcinoma (HCC), which …

Cet article Transgene: First Patient Dosed in a Phase 1/2 Trial of
Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

NEXT ARTICLE

More From BioPortfolio on "Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...